Trademark: 86365261
Word
HEGOLTA
Status
Dead
Status Code
710
Status Date
Friday, March 18, 2022
Serial Number
86365261
Registration Number
4806825
Registration Date
Tuesday, September 8, 2015
Mark Type
4000
Filing Date
Wednesday, August 13, 2014
Published for Opposition
Tuesday, June 23, 2015
Cancellation Date
Friday, March 18, 2022

Trademark Owner History
Glaxo Group Limited - Original Registrant

Classifications
5 Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
The wording "HEGOLTA" has no meaning in a foreign language.

Trademark Events
Mar 18, 2022
Cancelled Sec. 8 (6-Yr)
Sep 8, 2020
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Sep 8, 2015
Registered-Principal Register
Jun 23, 2015
Teas Change Of Correspondence Received
Jun 23, 2015
Official Gazette Publication Confirmation E-Mailed
Jun 23, 2015
Published For Opposition
Jun 3, 2015
Notification Of Notice Of Publication E-Mailed
May 15, 2015
Law Office Publication Review Completed
May 14, 2015
Approved For Pub - Principal Register
May 14, 2015
Teas/Email Correspondence Entered
May 14, 2015
Correspondence Received In Law Office
May 11, 2015
Assigned To Lie
May 6, 2015
Teas Response To Suspension Inquiry Received
Nov 14, 2014
Notification Of Letter Of Suspension E-Mailed
Nov 14, 2014
Letter Of Suspension E-Mailed
Nov 14, 2014
Suspension Letter Written
Nov 14, 2014
Assigned To Examiner
Aug 22, 2014
New Application Office Supplied Data Entered In Tram
Aug 16, 2014
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24